Welcome to our dedicated page for Janux Therapeutics SEC filings (Ticker: JANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Janux Therapeutics filings document a clinical-stage biopharmaceutical issuer developing tumor-activated immunotherapies through the TRACTr, TRACIr and ARM platforms. Recent 8-K reports furnish financial results and business updates covering clinical programs such as JANX007, JANX014, JANX011 and JANX008, as well as cash-position commentary and pipeline prioritization.
The company’s regulatory record also includes a material definitive agreement for the Bristol Myers Squibb collaboration, with license, development, commercialization, milestone and royalty terms. Proxy and governance filings document director elections, board-classification matters, executive compensation, pay-versus-performance disclosure and officer or director changes.
Janux Therapeutics, Inc. reported an equity compensation grant to its Chief Medical Officer, William Go. On February 2, 2026, he received 44,000 shares of common stock in the form of restricted stock units that vest in four equal annual installments beginning February 1, 2027.
He was also granted a stock option for 154,000 shares of common stock at an exercise price of $13.99 per share. Twenty-five percent of this option vests on February 26, 2027, with the remaining shares vesting in equal monthly installments over the following three years. Both holdings are reported as directly owned.
Janux Therapeutics, Inc. Chief Medical Officer William Go filed an initial ownership report on Form 3. The filing states that no Janux common stock or derivative securities are beneficially owned. This establishes his baseline insider ownership position as zero under SEC reporting rules.
Janux Therapeutics shareholder plans a sizable stock sale. A person identified as Andy Meyer has filed to sell 178,767 shares of JANX common stock through Morgan Stanley Smith Barney LLC on or around 01/26/2026 on the NASDAQ. The filing lists an aggregate market value of $2,601,113.48 for these shares, with 60,147,807 shares of common stock outstanding. The shares to be sold were acquired on 01/26/2026 by exercising options under a registered plan for cash. Over the prior three months, the same seller reported multiple JANX stock sales totaling several tranches, including 118,122 shares on 01/23/2026 and 16,665 shares on 10/28/2025.
JANX insider Andy Meyer filed a notice of proposed sale under Rule 144 to sell 118,122 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,738,389.66 and 60,147,807 shares outstanding.
The shares were acquired on 01/23/2026 by exercising options under a registered plan and paid for in cash on the same date. In the past three months, Meyer has sold additional JANX common shares, including 16,665 shares on 10/28/2025 for gross proceeds of $500,314.00, under separate transactions.
Janux Therapeutics entered an exclusive license and collaboration agreement with Bristol-Myers Squibb to develop and commercialize a novel tumor-activated therapeutic for solid tumors. Janux will handle preclinical work through IND submission for one drug candidate, after which BMS will take over global development, manufacturing and commercialization, while Janux supplies product for early clinical trials for a limited period.
Janux receives a $15 million upfront payment and may earn up to $785 million in development, regulatory and sales milestones, including $35 million tied to a near-term milestone. BMS will also pay tiered royalties from high-single digit to low-double digit percentages on annual net sales of any approved products, with royalty terms linked to patent life, regulatory exclusivity and time from first commercial sale.
FMR LLC and Abigail P. Johnson filed Amendment No. 4 to a Schedule 13G/A reporting their beneficial ownership of common stock of Janux Therapeutics Inc. As of the event date of 12/31/2025, they report beneficial ownership of 3,512,384 shares of common stock, representing 5.8% of the class. FMR LLC has sole voting power over 3,505,856 shares and sole dispositive power over 3,512,384 shares, while Abigail P. Johnson reports sole dispositive power over the same 3,512,384 shares.
The filing states that one or more other persons have the right to receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the outstanding common stock. The securities are described as being acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Janux Therapeutics.
Janux Therapeutics (JANX) reported an insider equity transaction by its Chief Business Officer. On 11/14/2025, the officer exercised a stock option for 3,333 shares of common stock at $10.59 per share and on the same date sold 3,333 shares at $30 per share. After these transactions, the officer beneficially owned 84,974 shares of Janux common stock directly and 118,101 stock options. The sale was conducted under a Rule 10b5-1 trading plan adopted on 09/30/2024. The filing also notes prior acquisitions of 1 share on 11/15/2024 and 2,834 shares on 05/15/2025 through the company’s 2021 Employee Stock Purchase Plan.
Janux Therapeutics (JANX) reported Q3 2025 results. Collaboration revenue reached $10,000 (vs. $439 in Q3 2024), driven by a $10.0 million Merck milestone achieved in August tied to the first collaboration target. R&D expense was $34,629 and G&A was $10,622, leading to a net loss of $24,313, or $0.39 per share.
For the nine months, revenue totaled $10,000, operating expenses were $125,266, and net loss was $81,679. Interest income contributed $33,587 year-to-date. Cash and cash equivalents were $48,389 and short‑term investments were $940,604 as of September 30, supporting total assets of $1,024,766. Net cash used in operating activities was $53,693 for the period. Shares outstanding were 60,123,602 at quarter end; 60,147,807 were outstanding as of November 4, 2025.
The company states it has sufficient capital to fund operations for at least 12 months. Performance obligations under the Merck collaboration were completed as of September 30, 2025, with future milestones recognized only upon occurrence.
Janux Therapeutics, Inc. filed a current report to note that it released a press release with its financial results for the three and nine months ended September 30, 2025. The company is furnishing, not filing, this information, which means the press release is not subject to certain liability provisions under the securities laws and is not automatically incorporated into other SEC filings. Investors interested in the detailed revenue, expense, and earnings figures for this period would need to review the attached Exhibit 99.1 press release referenced in the report.
Janux Therapeutics (JANX) Form 4: The company’s Chief Business Officer reported two option exercises and a subsequent sale on 10/28/2025. He exercised 9,999 options at $4.21 and 6,666 options at $10.59, then sold 16,665 shares.
The sale’s weighted average price was $30.0622, with trades between $30.00 and $30.49, executed under a Rule 10b5-1 trading plan adopted on September 30, 2024. Following these transactions, he directly beneficially owned 82,139 shares.